JP2017526371A - 化合物および方法 - Google Patents

化合物および方法 Download PDF

Info

Publication number
JP2017526371A
JP2017526371A JP2017511702A JP2017511702A JP2017526371A JP 2017526371 A JP2017526371 A JP 2017526371A JP 2017511702 A JP2017511702 A JP 2017511702A JP 2017511702 A JP2017511702 A JP 2017511702A JP 2017526371 A JP2017526371 A JP 2017526371A
Authority
JP
Japan
Prior art keywords
cell
antigen
cells
cytokine
antigen molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017511702A
Other languages
English (en)
Japanese (ja)
Inventor
ホッグセット、アンダース
ヨハンセン、パル
Original Assignee
ピーシーアイ バイオテック エイエス
ピーシーアイ バイオテック エイエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201415247A external-priority patent/GB201415247D0/en
Priority claimed from GB201420773A external-priority patent/GB201420773D0/en
Application filed by ピーシーアイ バイオテック エイエス, ピーシーアイ バイオテック エイエス filed Critical ピーシーアイ バイオテック エイエス
Publication of JP2017526371A publication Critical patent/JP2017526371A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2017511702A 2014-08-28 2015-08-28 化合物および方法 Pending JP2017526371A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201415247A GB201415247D0 (en) 2014-08-28 2014-08-28 Compound and method
GB1415247.4 2014-08-28
GB1420773.2 2014-11-21
GB201420773A GB201420773D0 (en) 2014-11-21 2014-11-21 Compound and method
PCT/EP2015/069794 WO2016030529A1 (en) 2014-08-28 2015-08-28 Compound and method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020123157A Division JP7079819B2 (ja) 2014-08-28 2020-07-17 化合物および方法

Publications (1)

Publication Number Publication Date
JP2017526371A true JP2017526371A (ja) 2017-09-14

Family

ID=54065872

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017511702A Pending JP2017526371A (ja) 2014-08-28 2015-08-28 化合物および方法
JP2020123157A Active JP7079819B2 (ja) 2014-08-28 2020-07-17 化合物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020123157A Active JP7079819B2 (ja) 2014-08-28 2020-07-17 化合物および方法

Country Status (9)

Country Link
US (1) US10537639B2 (enExample)
EP (1) EP3185901B1 (enExample)
JP (2) JP2017526371A (enExample)
KR (1) KR102678732B1 (enExample)
CN (1) CN108136016A (enExample)
AU (1) AU2015308345B9 (enExample)
BR (1) BR112017003486A2 (enExample)
NZ (1) NZ729408A (enExample)
WO (1) WO2016030529A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020170330A1 (ja) 2019-02-19 2020-08-27 大塚電子株式会社 光線力学的療法条件パラメータの決定方法および光線力学的療法装置

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109912607B (zh) * 2018-12-11 2021-01-22 南华大学 一类卟啉-白杨素复合物及其抗肿瘤活性

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520823A (ja) * 2000-12-13 2004-07-15 イミュネックス・コーポレーション 不死樹状細胞系の作製方法
WO2005097976A1 (ja) * 2004-04-06 2005-10-20 Ehime University 抗原パルスして得られた樹状細胞
JP2007510759A (ja) * 2003-11-12 2007-04-26 セリオン・バイオロジックス・コーポレーション 膵癌を処置および予防するためのカスタムベクター
JP2011522837A (ja) * 2008-06-06 2011-08-04 ベイラー リサーチ インスティテュート 呼吸器多核体ウイルスによる樹状細胞の寛容誘導
WO2013189663A1 (en) * 2012-05-15 2013-12-27 Pci Biotech As Conjugate of a photosensitiser and chitosan and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
KR20080080685A (ko) 2000-11-29 2008-09-04 피씨아이 바이오테크 에이에스 사이토졸 내로의 분자 전달을 위한 광화학적 내부이행
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
WO2005100547A1 (ja) * 2004-04-06 2005-10-27 Techno Network Shikoku Co., Ltd. 抗原パルスして得られた樹状細胞
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
US20160040128A1 (en) 2013-03-15 2016-02-11 Pci Biotech As Method
WO2015028575A1 (en) 2013-08-28 2015-03-05 Pci Biotech As Immunisation method by photochemical internalisation
CN105873585A (zh) 2013-08-28 2016-08-17 Pci生物技术公司 用于疫苗接种或免疫的化合物和方法
CA2945220C (en) 2014-04-11 2023-09-26 Pci Biotech As Method of treating melanoma

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520823A (ja) * 2000-12-13 2004-07-15 イミュネックス・コーポレーション 不死樹状細胞系の作製方法
JP2007510759A (ja) * 2003-11-12 2007-04-26 セリオン・バイオロジックス・コーポレーション 膵癌を処置および予防するためのカスタムベクター
WO2005097976A1 (ja) * 2004-04-06 2005-10-20 Ehime University 抗原パルスして得られた樹状細胞
JP2011522837A (ja) * 2008-06-06 2011-08-04 ベイラー リサーチ インスティテュート 呼吸器多核体ウイルスによる樹状細胞の寛容誘導
WO2013189663A1 (en) * 2012-05-15 2013-12-27 Pci Biotech As Conjugate of a photosensitiser and chitosan and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAKERUD MONIKA; WAECKERLE-MEN YING; SELBO PAL KRISTIAN; ET AL: "INTRADERMAL PHOTOSENSITISATION FACILITATES STIMULATION OF MHC CLASS-I RESTRICTED CD8 T-CELL 以下備考", JOURNAL OF CONTROLLED RELEASE, vol. 174, JPN5017007288, 23 November 2013 (2013-11-23), NL, pages 143 - 150, ISSN: 0004236502 *
WAECKERLE-MEN YING; MAURACHER ANDREA; HKERUD MONIKA; ET AL: "PHOTOCHEMICAL TARGETING OF ANTIGENS TO THE CYTOSOL FOR STIMULATION OF MHC 以下備考", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. VOL:85, NR:1, JPN5017007289, 24 February 2013 (2013-02-24), pages 34 - 41, ISSN: 0004236503 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020170330A1 (ja) 2019-02-19 2020-08-27 大塚電子株式会社 光線力学的療法条件パラメータの決定方法および光線力学的療法装置

Also Published As

Publication number Publication date
WO2016030529A1 (en) 2016-03-03
EP3185901C0 (en) 2023-10-04
NZ729408A (en) 2021-12-24
CN108136016A (zh) 2018-06-08
JP2020182486A (ja) 2020-11-12
AU2015308345A1 (en) 2017-03-16
EP3185901B1 (en) 2023-10-04
AU2015308345B2 (en) 2020-12-10
US10537639B2 (en) 2020-01-21
EP3185901A1 (en) 2017-07-05
KR102678732B1 (ko) 2024-06-25
AU2015308345B9 (en) 2020-12-24
US20170252441A1 (en) 2017-09-07
CA2959207A1 (en) 2016-03-03
KR20170047336A (ko) 2017-05-04
BR112017003486A2 (pt) 2018-01-16
JP7079819B2 (ja) 2022-06-02

Similar Documents

Publication Publication Date Title
JP7536737B2 (ja) Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
US9339535B2 (en) Vaccines and immunopotentiating compositions and methods for making and using them
JP2007501602A5 (enExample)
Haug et al. Photochemical internalization of peptide antigens provides a novel strategy to realize therapeutic cancer vaccination
US8834899B2 (en) Photodynamic therapy-generated mesothelioma vaccine
JP2021514661A (ja) サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物
JP7079819B2 (ja) 化合物および方法
US20160040128A1 (en) Method
US10973896B2 (en) Treatment or prevention of melanoma using photochemical internalization of a melanoma antigen
EP2989121A1 (en) Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
AU2018233208B2 (en) Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use
WO2015028575A1 (en) Immunisation method by photochemical internalisation
KR101857705B1 (ko) 백신용 분자 아쥬반트로서 뇌하수체 아데닐산 고리화효소 활성화 펩타이드의 용도
CA2959207C (en) Expression of an antigenic molecule on the surface of a cell using a photosensitizing agent and a cytokine
US20190038740A1 (en) MHC Class I Associated Hepatitis B Peptides
Qin et al. Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines
TWI228993B (en) Fusion antigen specific for a target cell

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200319